{"url_path":"/sec/mcrb/8-k/2026-07-08/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-08","source_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","accession_number":"0001193125-26-298525","cik":"0001609809","ticker":"MCRB","issuer_name":"Seres Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","primary_entity_key":"0001609809","primary_entity_name":"Seres Therapeutics, Inc."},"word_count":261,"has_tables":true,"body_markdown":"Item 5.02.\n\nDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nAs reported below under Item 5.07 of this Current Report on Form 8-K (this “Current Report”), on July 8, 2026, Seres Therapeutics, Inc. (the “Company”) reconvened its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), which had been adjourned from June 9, 2026 due to a lack of quorum. At the Annual Meeting, the Company’s stockholders approved an amendment and restatement of the Seres Therapeutics, Inc. 2025 Incentive Award Plan (the “2025 Plan”) to increase the number of shares of the Company’s common stock available for issuance under the 2025 Plan by 900,000 shares. The amendment and restatement of the 2025 Plan was approved by the Company’s Board of Directors on April 22, 2026, subject to and effective upon stockholder approval of the amendment and restatement of the 2025 Plan at the Annual Meeting.\n\nThe terms and conditions of the 2025 Plan, as amended and restated, are described in the section entitled “Proposal 4 — Approval of the Amendment and Restatement of the Seres Therapeutics, Inc. 2025 Incentive Award Plan” in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on April 27, 2026 (the “Definitive Proxy Statement”). The foregoing description of the 2025 Plan does not purport to be complete and is qualified in its entirety by reference to the complete text of the 2025 Plan, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference."}